Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

LISATA THERAPEUTICS, INC. Director's Dealing 2019

Jan 10, 2019

34931_dirs_2019-01-10_2fd3ac20-d404-43b1-be5c-d62e8a57cf7e.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: CALADRIUS BIOSCIENCES, INC. (CLBS)
CIK: 0000320017
Period of Report: 2019-01-08

Reporting Person: KLOSK STEVEN M (Director)

Non-Derivative Transactions

Date Security Code Shares Price A/D Holdings After Ownership
2019-01-08 Common Stock A 8747 Acquired 17812 Direct

Footnotes

F1: Represents 8,747 shares underlying restricted stock granted under the 2018 Equity Incentive Compensation Plan which were awarded on January 8, 2018 and which vested on January 8, 2019.